RxDoctor Payments Data

Mailenys Ortega, NP

Family · Miami, FLNPI 1154996056

Payments from drug & device makers

$9,265in general payments, 2019–2025

Across 111 payments — averaging $83.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Bristol Myers Squibb$1K
  • AbbVie$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$345
  • Janssen Scientific Affairs, LLC$281
  • plus $779 from 9 others

What the payments were for

  • Consulting fees$4,36247%
  • Travel & lodging$92410%
  • Food & beverage$3,77941%
  • Education$2002%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,265 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$16,509
Medicare patients
98
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab122$3,238,133
Skyrizi On-BodyRisankizumab-Rzaa58$1,233,723
Humira(Cf) PenAdalimumab70$943,263
RinvoqUpadacitinib29$241,360
XeljanzTofacitinib Citrate11$63,460
XifaxanRifaximin13$38,287
Mesalamine49$25,731
Famotidine47$665
LoperamideLoperamide Hcl20$589
Balsalazide Disodium12$557
Dicyclomine Hcl16$486
Pantoprazole Sodium69$442
Sulfasalazine25$442
Sucralfate14$361
Ondansetron Hcl14$260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$3,369$3,238,133122 claims
AbbVieRinvoq$1,004$241,36029 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$224$38,28713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →